Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01645709
Recruitment Status : Terminated (Sponsor decision to terminate study)
First Posted : July 20, 2012
Results First Posted : September 5, 2014
Last Update Posted : September 5, 2014
Sponsor:
Collaborator:
Health Decisions
Information provided by (Responsible Party):
Calosyn Pharma, Inc.

Tracking Information
First Submitted Date  ICMJE July 17, 2012
First Posted Date  ICMJE July 20, 2012
Results First Submitted Date  ICMJE August 26, 2014
Results First Posted Date  ICMJE September 5, 2014
Last Update Posted Date September 5, 2014
Study Start Date  ICMJE April 2012
Actual Primary Completion Date February 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 18, 2012)
Compare Efficacy of Verapmil vs Placebo at Week 4 [ Time Frame: 4 weeks ]
To compare the efficacy of IA verapamil versus IA placebo for pain relief using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) at week 4.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01645709 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 18, 2012)
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • WOMAC total and subscale scores for pain, function, and stiffness at each visit
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • WOMAC pain subscale as measured from 2 to 12 weeks post-treatment using an AUC approach
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • In-clinic 24-hour recall pain intensity using the 0-10 numerical rating scale (NRS) at each visit
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Difference in the current in-clinic pain intensity using the 0-10 NRS before and after exercise at each visit
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Response rate
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Patient Global Impression of Change (PGIC)
  • Compare Efficacy of Verapamil to Placebo Compared to Baseline [ Time Frame: 13 weeks ]
    To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Rescue medication use
  • Number of Subjects With Adverse Events [ Time Frame: 13 weeks ]
    Compare the safety of IA verapamil versus IA placebo using adverse events (AEs) as a comparator
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee
Official Title  ICMJE CS-201: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intra-Articular Verapamil in the Treatment of JoinT Pain in Subjects With Osteoarthritis of the Knee
Brief Summary This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of Intra-Articular (IA) verapamil in the treatment of joint pain in patients with knee osteoarthritis (OA). Subjects will discontinue all analgesic medications for the entire duration of the study, except for acetaminophen (taken on an as needed basis at no more than 2 g/day). At visit 2, subjects who meet all entry criteria will be randomized to receive a single injection of IA verapamil or IA placebo at a ratio of 1:1. Treatments will be given with fluoroscopy or ultrasound to confirm needle placement. Subjects will be monitored for blood pressure and heart rate (sitting and standing) for at least 1 hour post-injection. Subjects will be evaluated at weeks 1, 2, 3, 4, 6, 8, and 12 after treatment.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis of the Knee
Intervention  ICMJE
  • Drug: Verapamil
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Verapamil
    Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
    Intervention: Drug: Verapamil
  • Placebo Comparator: Placebo
    Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: February 6, 2014)
81
Original Estimated Enrollment  ICMJE
 (submitted: July 18, 2012)
200
Study Completion Date  ICMJE Not Provided
Actual Primary Completion Date February 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to participate in the study:

  1. Be 35-75 years of age and in good general medical and psychological health.
  2. Be able to speak, read, write, and understand English, understand the consent form, complete study-related procedures, and communicate with the study staff.
  3. Have OA of at least 1 knee (target knee) for at least 6 months and meet all the following criteria:

    • OA documented by standing X-rays anterior-posterior patella-femoral view taken within 1 month of screening visit indicating Kellgren-Lawrence Grade 2 to early-stage Grade 4 radiographic stage of the knee;
    • Have pain associated with OA of the target knee for at least 25 of the last 30 days; c. Meet the American College of Rheumatology clinical classification criteria, defined as having pain in the target knee and at least 3 of the following 6 items:

      • Age > 50;
      • Morning stiffness <30 minutes;
      • Crepitus on active motion;
      • Bony tenderness;
      • Bony enlargement;
      • No palpable warmth of synovium.
  4. Target knee does not have any type of orthopedic and/or prosthetic device.
  5. Based on standard physical examination of the target knee, does not have any neurovascular deficits, any skin abnormalities, any meniscal abnormalities, or any ligament instability.
  6. At treatment visit 2 prior to randomization, have a score of at least 20 on the WOMAC pain subscale (questions 1-5) for the target knee and an in-clinic average pain intensity score of at least 4/10 on the 0-10 NRS for the 24-hour recall.
  7. Be willing to maintain any present stable treatment modalities (e.g., acupuncture or physical therapy) and be willing to refrain from initiating any new treatment modalities.
  8. Be willing to stop taking nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for the duration of the study.
  9. If female of child-bearing potential (ie, not medically or surgically sterilized or not post-menopausal more than 1 year) or fertile male with sexual partner of childbearing potential, be willing to use adequate and reliable contraception throughout the study (eg, abstinence or barrier with additional spermicidal foam or jelly, or the use of intrauterine device or hormonal contraception by female subjects and partners of male subjects).
  10. Not be enrolled in any other clinical trial and not have used any investigational drug within 1 month.

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible to participate:

  1. Have a Kellgren-Lawrence Grade 1 radiographic stage of the knee or have Kellgren-Lawrence Grade 4 radiographic end stage of the knee with bone on bone, ie, less than 2 mm joint space.
  2. Be a candidate for knee replacement within next 6 months.
  3. Have a body mass index > 35 kg/m2.
  4. Have a Hospital Anxiety and Depression Scale score >12 on either subscale or have an established history of major depressive disorder not controlled with medication.
  5. Have, in the Investigator's opinion, clinically significant abnormalities in clinical laboratory tests (hematology, clinical labs, urinalysis).
  6. Have a positive urine drug test for illegal drug substances at screening.
  7. Have, in the Investigator's opinion, clinically significant abnormalities in electrocardiogram readings
  8. If a female of childbearing potential, have a positive pregnancy test at screening.
  9. Have significant pain outside the target knee, including significant hip or back pain (bilateral knee OA will be allowed as long as target knee pain can be distinguished from contralateral knee pain and contralateral knee does not require treatment).
  10. Have pain affecting the target knee that is due to any etiology other than OA.
  11. Have documented history of inflammatory arthritis, including rheumatoid arthritis.
  12. Have a meniscal tear in the target knee.
  13. Have had viscosupplementation with hyaluronic acid products within 6 months prior to screening.
  14. Have failed to respond to prior treatment with viscosupplementation with hyaluronic acid products.
  15. Have had IA corticosteroid injections within 12 weeks or intramuscular or oral steroids within 4 weeks prior to screening.
  16. Have had surgery of the target knee within 6 months prior to screening.
  17. Have used opioids 4 or more days per week during in the past month prior to screening.
  18. Are allergic to, or intolerant of, acetaminophen.
  19. Have used verapamil within the past 4 weeks or are allergic or intolerant to verapamil.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 35 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT01645709
Other Study ID Numbers  ICMJE CS-201
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Calosyn Pharma, Inc.
Study Sponsor  ICMJE Calosyn Pharma, Inc.
Collaborators  ICMJE Health Decisions
Investigators  ICMJE Not Provided
PRS Account Calosyn Pharma, Inc.
Verification Date August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP